Rodríguez LI

Language: Spanish
References: 18
Page: 436-439
PDF size: 58.86 Kb.

Text Extraction

Non Abstract

REFERENCES

1. Ropper AH. The Guillain-Barré’s syndrome. N Engl J Med 1992; 326(17): 1130-6.

2. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré’s syndrome. Ann Neurol 1990; 27 Suppl: S21-4.

3. Yuki N, Hirata K. Preserved tendon reflexes in Campylobacter neuropathy. Ann Neurol 1998; 43(4): 546-7.

4. Ho TW, Hsieh ST, Nachamkin I, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 1997a; 48(3): 717-24.

5. Kanra G, Ozon A, Vajsar J, Castagna L, Secmeer G, Topaloglu H. Intravenous immunoglobulin treatment in children with Guillain-Barré’s syndrome. Eur J Paediatr Neurol 1997; 1(1): 7-12.

6. Aspinall GO, Fujimoto S, McDonald AG, Pang H, Kurjanczyk LA, Penner JL. Lipopolysaccharides from Campylobacter jejunii associated with Guillain-Barré’s syndrome patients mimic human gangliosides in structure. Infect Immun 1994; 62(5): 2122-5.

7. Baoxun Z, Yinchang Y, Huifen H, Xiuqin L. Acute polyradiculitis (Guillain-Barré’s syndrome): an epidemiological study of 156 cases observed in Beijing. Ann Neurol 1981; 9 Suppl 1: 146-8.

8. Griffin JW, Li CY, Ho TW, et al. Guillain-Barré’s syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain 1995; 118(Pt 3): 577-95.

9. Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barré’s syndrome. Ann Neurol 1996a; 39(1): 17-28.

10. Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré’s syndrome. J Neurocytol 1996b; 25(1): 33-51.

11. Saperstein DS, Amato AA, Katz JS, Barohn RJ. Immune-mediated polyneuropathies. In: Pourmand R, editor. Neuromuscular diseases: Expert clinicians’ views. Boston: Butterworth-Heinemann, 2001: 135-44.

12. Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré’s syndrome: clinical associations and outcome. Exchange/Sandoglobulin Guillain-Barré’s Syndrome Trial Group. Ann Neurol 1998; 44(5): 780-8.

13. Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain-Barré’s syndromes. Neurology 2003; 61(4): 471-4.

14. Bernsen RA, De Jager AE, Schmitz PI, Van der Meche FG. Residual physical outcome and daily living 3 to 6 years after Guillain-Barré’s syndrome. Neurology 1999; 53(2): 409-10.

15. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999; 22(11): 1479-97.

16. Hurley TJ, Brunson AD, Archer RL, Lefler SF, Quirk JG Jr. Landry Guillain-Barré’s Strohl syndrome in pregnancy: Report of three cases treated with plasmapheresis. Obstet Gynecol 1991; 78(3 Pt 2): 482-5.

17. Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain-Barré’s syndromes. Neurology 2003; 61(4): 471-4.

18. Hughes R, Wijdicks E, Barohn R, Benson E, Cornblath D, Hahn A. Practice parameter: Immunotherapy for Guillain–Barré’s syndrome. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 736–40.